Press Release January 28, 2022Regeneron and Sanofi Provide Regulatory Update on Libtayo® (cemiplimab-rwlc) in Advanced Cervical Cancer 0 0 Share
Company Ticker News January 21, 2022Regeneron (REGN) Rides on Solid Product Portfolio: Should You Buy? 0 0 Share
Company Ticker News January 19, 2022Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease 0 0 Share
Press Release January 19, 2022FDA Accepts for Review Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy for First-line Treatment of Advanced NSCLC 0 0 Share
Company Ticker News January 19, 2022Regeneron Announces FDA Accepts For Review Libtayo In Combination With Chemotherapy For First-Line Treatment Of Advanced NSCLC 0 0 Share
Press Release January 19, 2022Second Positive Phase 3 Dupixent® (dupilumab) Trial Confirms Significant Improvements for Patients with Prurigo Nodularis 0 0 Share
Press Release January 19, 2022Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis 0 0 Share
Company Ticker News January 14, 2022Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? 0 0 Share
Company Ticker News January 11, 2022Regeneron Pharmaceuticals, Inc. (REGN) CEO Len Schleifer Presents at 40th Annual JPMorgan Virtual Healthcare Conference (Transcript) 0 0 Share
